Showing results (121-130 of 141) with videos related to
Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue SarcomasGeraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1FSenthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2012
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanomaMichael A Davies, Patricia S Fox, Nicholas E Papadopoulos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaRichard L Piekarz, Robin Frye, Maria Turner, et al.Neuro-Oncology|January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.NPJ Breast Cancer|July 20, 2017
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialKerin Adelson, Bhuvaneswari Ramaswamy, Joseph A Sparano, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.Haematologica|June 27, 2012
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp, Elizabeth Garrett-Mayer, Elihu H Estey, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2020
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)Neesha C Dhani, Hal W Hirte, Lisa Wang, et al.Blood|October 18, 2011
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemiaJudith E Karp, Tatiana I Vener, Mitch Raponi, et al.Pageof 15